题名 | Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody-drug conjugates-induced interstitial lung disease/pneumonitis: An expert consensus in China |
作者 | Chunwei Xu1,2,3; Zhanhong Chen4; Yuanli Xia5; Yanxia Shi6; Peifen Fu7; Yiding Chen8; Xian Wang9; Lili Zhang10; Hengyu Li11; Wenyan Chen12; Jianfei Fu13; Liming Huang14; Jingde Shu15; Ouchen Wang16; Weizhu Wu17; Bojian Xie18; Ting Wang19; Weiping Zhang20; Shurong Shen21; Qun Li22; Ting Luo23; Bin Zhang24; Yanru Xie25; Hongxia Wang26; Qian Wang27; Wenxian Wang1; Ziming Li28; Zhengbo Song1; Wenfeng Fang6; Wenzhao Zhong29; Yongchang Zhang30; Ping Zhan3; Hongbing Liu3; Tangfeng Lv3; Liyun Miao31; Lingfeng Min32; Feng Wang33; Rui Meng34; Youcai Zhu35; Lin Wang36; Bing Wan37; Dong Wang3; Yue Hao1; Jianya Zhou5; Long Huang38; Zhang Zhang39; Donglai Lv40; Meiyu Fang1; Yuanzhi Lu41; Lu Si42; Yong Song3; Xiaojia Wang4,19
|
发表日期 | 2024-08-02 |
发表期刊 | Cancer 影响因子和分区 |
语种 | 英语 |
原始文献类型 | Journal Article |
关键词 | HER2‐ADC–related adverse events ILD management antibody–drug conjugate (ADC) human epidermal growth factor receptor 2 (HER2) interstitial lung disease (ILD) pneumonitis trastuzumab deruxtecan |
其他关键词 | TRASTUZUMAB EMTANSINE T-DM1 ; OPEN-LABEL ; PHYSICIANS CHOICE ; CANCER ; DERUXTECAN ; DISEASE ; MULTICENTER ; PHASE-2 ; SAFETY ; TAXANE |
摘要 | Antibody-drug conjugates (ADCs) have demonstrated effectiveness in treating various cancers, particularly exhibiting specificity in targeting human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Recent advancements in phase 3 clinical trials have broadened current understanding of ADCs, especially trastuzumab deruxtecan, in treating other HER2-expressing malignancies. This expansion of knowledge has led to the US Food and Drug Administration's approval of trastuzumab deruxtecan for HER2-positive and HER2-low breast cancer, HER2-positive gastric cancer, and HER2-mutant nonsmall cell lung cancer. Concurrent with the increasing use of ADCs in oncology, there is growing concern among health care professionals regarding the rise in the incidence of interstitial lung disease or pneumonitis (ILD/p), which is associated with anti-HER2 ADC therapy. Studies on anti-HER2 ADCs have reported varying ILD/p mortality rates. Consequently, it is crucial to establish guidelines for the diagnosis and management of ILD/p in patients receiving anti-HER2 ADC therapy. To this end, a panel of Chinese experts was convened to formulate a strategic approach for the identification and management of ILD/p in patients treated with anti-HER2 ADC therapy. This report presents the expert panel's opinions and recommendations, which are intended to guide the management of ILD/p induced by anti-HER2 ADC therapy in clinical practice. |
资助项目 | Zhejiang Traditional Chinese Medicine Science Fund Project[2024ZL372];National Natural Science Foundation of China of Zhejiang Cancer Hospital Cultivation Project[PY2023006];Natural Science Foundation of Zhejiang Province[Q24H160110];Xisike-Hengrui Cancer Research Foundation[Y-2022HER2AZMS-0379];China Postdoctoral Science Foundation[2022M723207];Medical Scientific Research Foundation of Zhejiang Province, China[2023KY666];Medical Scientific Research Foundation of Zhejiang Province, China[2024KY812] |
出版者 | WILEY |
ISSN | 0008-543X |
EISSN | 1097-0142 |
卷号 | 130期号:S17页码:3054-3066 |
DOI | 10.1002/cncr.35475 |
页数 | 13 |
WOS类目 | Oncology |
WOS研究方向 | Oncology |
WOS记录号 | WOS:001282940000001 |
收录类别 | PUBMED ; SCIE ; SCOPUS |
URL | 查看原文 |
PubMed ID | 39092590 |
SCOPUSEID | 2-s2.0-85200271924 |
通讯作者地址 | [Wang, Xiaojia]Chinese Acad Sci, Zhejiang Canc Hosp, Hangzhou Inst Med, Dept Breast Canc Internal Med, Hangzhou 310022, Zhejiang, Peoples R China. |
Scopus学科分类 | Oncology;Cancer Research |
SCOPUS_ID | SCOPUS_ID:85200271924 |
引用统计 | |
文献类型 | 期刊论文 |
条目标识符 | https://kms.wmu.edu.cn/handle/3ETUA0LF/217103 |
专题 | 附属第一医院 第一临床医学院(信息与工程学院)、附属第一医院 附属台州医院 其他_附属台州医院(浙江省台州医院) |
作者单位 | 1.Department of Chemotherapy, Chinese Academy of Sciences University Cancer Hospital (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China.; 2.Institute of Cancer and Basic Medicine, Chinese Academy of Sciences, Hangzhou, Zhejiang, China.; 3.Department of Respiratory Medicine, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China.; 4.Department of Breast Cancer Internal Medicine, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, Zhejiang, China.; 5.Department of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.; 6.State Key Laboratory of Oncology in South China, Department of Medical Oncology, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.; 7.Department of Breast Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.; 8.Key Laboratory of Cancer Prevention and Intervention, Department of Breast Surgery and Oncology, Cancer Institute, China National Ministry of Education, Second Affiliated Hospital of Zhejiang University School of Medicine, Cancer Center, Zhejiang University, Hangzhou, Zhejiang, China.; 9.Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China.; 10.Department of Oncology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Nanjing, Jiangsu, China.; 11.Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Naval Medical University, Shanghai, China.; 12.Department of Medical Oncology, Nanchang People's Hospital, Nanchang, Jiangxi, China.; 13.Department of Medical Oncology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang, China.; 14.Department of General Surgery (Breast and Thyroid Surgery), Shaoxing People's Hospital, Shaoxing Hospital, Zhejiang University School of Medicine, Shaoxing, Zhejiang, China.; 15.Department of Surgical Oncology, Quzhou Hospital of Zhejiang University, Quzhou, Zhejiang, China.; 16.Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.; 17.Department of Breast and Thyroid Surgery, The Affiliated Lihuili Hospital, Ningbo University, Ningbo, Zhejiang, China.; 18.Department of Breast and Thyroid Surgery, Taizhou Hospital of Zhejiang Province, Affiliated with Wenzhou Medical University, Linhai, Zhejiang, China.; 19.Department of Medical Oncology, Yiwu Hospital, Affiliated with Hangzhou Medical College, Yiwu, Zhejiang, China.; 20.Laboratory for Core Technology of Traditional Chinese Medicine Quality Improvement and Transformation, College of Pharmaceutical Science, The Third Affiliated Hospital, Academy of Chinese Medical Science, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.; 21.Department of Oncology, Wenzhou Central Hospital, Wenzhou, Zhejiang, China.; 22.Department of Medical Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.; 23.Department of Breast Center, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.; 24.Key Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Cancer Center, Zhejiang University, Hangzhou, Zhejiang, China.; 25.Department of Oncology, Lishui Municipal Central Hospital, Lishui, Zhejiang, China.; 26.Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; 27.Department of Respiratory Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, Jiangsu, China.; 28.Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.; 29.Guangdong Lung Cancer Institute, Guangdong Provincial Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, Guangzhou, Guangdong, China.; 30.Lung Cancer and Gastrointestinal Unit, Department of Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China.; 31.Department of Respiratory Medicine, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China.; 32.Department of Respiratory Medicine, Clinical Medical School of Yangzhou University, Subei People's Hospital of Jiangsu Province, Yangzhou, Jiangsu, China.; 33.Department of Internal Medicine, Cancer Center of PLA, Qinhuai Medical Area, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China.; 34.Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.; 35.Department of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital, The Third Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, China.; 36.Department of Pathology, Shanxi Academy of Medical Sciences, Shanxi Bethune Hospital, Taiyuan, Shanxi, China.; 37.Department of Respiratory Medicine, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.; 38.Department of Oncology, Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.; 39.International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education, Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, Guangzhou, Guangdong, China.; 40.Department of Clinical Oncology, The 901 Hospital of Joint Logistics Support Force of People Liberation Army, Hefei, Anhui, China.; 41.Department of Clinical Pathology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China.; 42.Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China. |
推荐引用方式 GB/T 7714 | Chunwei Xu,Zhanhong Chen,Yuanli Xia,et al. Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody-drug conjugates-induced interstitial lung disease/pneumonitis: An expert consensus in China[J]. Cancer,2024,130(S17):3054-3066. |
APA | Chunwei Xu., Zhanhong Chen., Yuanli Xia., Yanxia Shi., Peifen Fu., ... & Xiaojia Wang. (2024). Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody-drug conjugates-induced interstitial lung disease/pneumonitis: An expert consensus in China. Cancer, 130(S17), 3054-3066. |
MLA | Chunwei Xu,et al."Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody-drug conjugates-induced interstitial lung disease/pneumonitis: An expert consensus in China".Cancer 130.S17(2024):3054-3066. |
条目包含的文件 | 条目无相关文件。 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论